Physician profile
Ashley E Wiggers
NPI 1750039574
$1,524.60
in general payments reported to CMS, 2019-2025
22 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $348 · 2023: $433 · 2024: $336 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.10 | 2022-2024 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $145.66 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $107.14 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.60 | 2022-2025 | Trulance, Xifaxan |
| Aimmune Therapeutics, INC. | $85.39 | 2023-2025 | Vowst, Zenpep |
| Janssen Biotech, INC. | $54.86 | 2022-2025 | Simponi Aria, Stelara, Simponi |
| Ferring Pharmaceuticals INC. | $46.53 | 2022-2023 | Rebyota |
| Ardelyx, INC. | $41.22 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $35.36 | 2022-2023 | Sutab |
| Evoke Pharma, INC. | $26.30 | 2023 | Gimoti |
| Genzyme Corporation | $21.63 | 2023 | |
| Phathom Pharmaceuticals, INC. | $20.68 | 2025 | Voquezna |
| Pfizer INC. | $19.55 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.40 | 2024 | Iqirvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $17.51 | 2023 | Idacio |
| Amgen INC. | $17.00 | 2023 | Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $14.81 | 2023 | Dificid |
| Vivus LLC | $14.07 | 2022 | |
| Axonics, INC. | $13.42 | 2022 | |
| Organon LLC | $12.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wiggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.